Paige Yount, NP
Acute Care · Colorado Springs, CONPI 1467598797
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,500 of the $25,547 with a category attached, or 76.3%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 83.4% of it on its own, with 22 other manufacturers making up the rest. Among acute care clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $157.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$21K
- Medtronic$2K
- Abbott$511
- E.r. Squibb & Sons, L.L.C.$439
- Edwards Lifesciences$294
- Novartis$282
- plus $1K from 17 others
What the payments were for
- Consulting fees$130%
- Speaking & faculty fees$19,50076%
- Travel & lodging$1,0514%
- Food & beverage$4,96919%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 52 | $21,293 |
| Medtronic | 19 | $1,713 |
| Abbott | 5 | $511 |
| E.r. Squibb & Sons, L.L.C. | 21 | $439 |
| Edwards Lifesciences | 2 | $294 |
| Novartis | 15 | $282 |
| AstraZeneca | 10 | $150 |
| Boehringer Ingelheim | 3 | $145 |
| Amgen | 6 | $123 |
| Merck | 6 | $107 |
| Johnson & Johnson | 4 | $65 |
| Kestra Medical Technology Services, Inc. | 2 | $61 |
| Pfizer | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Impulse Dynamics (USA) Inc. | 1 | $39 |
| Bayer | 2 | $39 |
| Philips North America LLC | 2 | $39 |
| Cvrx, Inc. | 1 | $39 |
| Lexicon Pharmaceuticals, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Boston Scientific | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$19,940
- INSPIRIS RESILIA aortic valve$151
- SAPIEN 3 Ultra RESILIA$143
- TRICLIP$138
- SYMPLICITY G3$135
- MitraClip$121
- MitraClip System$113
- JARDIANCE$110
- LigaSure$101
How this compares
$25,547 in reported general payments places this provider in the 95th percentile of 239 acute care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 317 | $359,095 |
| EntrestoSacubitril/Valsartan | 166 | $192,996 |
| JardianceEmpagliflozin | 94 | $87,312 |
| XareltoRivaroxaban | 86 | $77,713 |
| Repatha SureclickEvolocumab | 36 | $36,016 |
| FarxigaDapagliflozin Propanediol | 31 | $26,915 |
| BrilintaTicagrelor | 25 | $20,448 |
| Metoprolol Succinate | 549 | $6,751 |
| Atorvastatin Calcium | 274 | $3,134 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 69 | $2,719 |
| Bumetanide | 66 | $2,539 |
| Losartan Potassium | 264 | $2,508 |
| Carvedilol | 199 | $1,730 |
| Flecainide Acetate | 40 | $1,516 |
| Spironolactone | 183 | $1,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $51 | $359,095317 claims |
| NovartisEntresto | $282 | $192,996166 claims |
| Boehringer IngelheimJardiance | $145 | $87,31294 claims |
| Johnson & JohnsonXarelto | $65 | $77,71386 claims |
| AstraZenecaFarxiga, Brilinta | $150 | $47,36356 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 acute care providers in Colorado.
Other acute care in Colorado Springs
- Tiffany MorganColorado Springs$590K
- Sarah NorwoodColorado Springs$20K
- Stefanie QuirkColorado Springs$6K
- Justine SummersColorado Springs$4K
- Patricia SanfordColorado Springs$4K
- Jennifer LynchColorado Springs$2K
- Cheryl RobsonColorado Springs$1K
- Sara PateColorado Springs$988
- Wendy StevensCortez$57K
- Peter ByrneLone Tree$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.